Comparative Pharmacology
Head-to-head clinical analysis: FLUDARA versus NELARABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDARA versus NELARABINE.
FLUDARA vs NELARABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludarabine is a purine nucleotide analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to cell death in dividing lymphocytes.
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
25 mg/m^2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
None Documented
None Documented
Fludarabine phosphate: 0.7-1 h (rapid dephosphorylation). Active metabolite 2-fluoro-ara-A: terminal t1/2 20-30 h (up to 40 h in renal impairment).
Clinical Note
moderateNelarabine + Digoxin
"Nelarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFludarabine + Digoxin
"Fludarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNelarabine + Digitoxin
"Nelarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFludarabine + Digitoxin
"Fludarabine may decrease the cardiotoxic activities of Digitoxin."
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Renal: 60% excreted unchanged in urine; biliary/fecal: <5% as metabolites.
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent